% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • frankfrazzano frankfrazzano May 31, 2014 7:00 AM Flag

    PD1 valuations and what does this mean for CLDX?

    ..going forward we all must ask the question post ASCO 2014 and the coming news about anti PD1/PDL1 ???

    If Oncologists are going to combine drugs from below w/ drugs like CDX-1127(Varli) and we are combining w/ drugs like ONT-10 from Oncothyreon than it seems to me that the Oncology Community is now declaring most CANCERS as Immunologically Manageable by Cocktail Therapies similiar to the way we treat HIV AIDS?

    That PFE was willing to pay AZN $120B and Im told the AZN PD-1 labeled MEDI 4736 was the driving force behind this massive buyout, than what the heck would a drug like Varli (if it proves to be valuable in Therapies) be really worth? $1B? $2B? $10B?

    That CLDX is not sitting by idly but reaching out to BMY to pair up with Nivolumab and recently ONT-10 tells me CLDX insiders know they have something very valuable...I think we are just beginning to appreciate the Tip of the Immune Ca Iceberg...the scientists have given us a peak into the Future of Cancer Treatment...and I for one have accumulated my largest HOLDING of CLDX ever since our old Avant days...

    I will be loathe to ever SELL another share given what is being explored!

    Table 1: PD1 and PDL1 pipeline

    Drug Lead company Most advanced indications

    Nivolumab Bristol-Myers Squibb Renal cell cancer, melanoma, NSCLC III
    Lambrolizumab Merck & Co. Melanoma II
    Pidilizumab* CureTech Colorectal cancer, melanoma, DLBCL II
    AMP-224‡ GlaxoSmithKline Solid tumours I

    MEDI-4736 AstraZeneca Solid tumours I
    MPDL3280A Roche Melanoma, solid tumours

    ...good luck all CLDX longs!


    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
17.82-0.19(-1.05%)Dec 1 3:59 PMEST